MicroPort® Endovastec™ Completes Its First Implantation of Castor™ Branched Stent-Graft and Hercules™-LP Stent Graft in Singapore

Singapore, 30 October 2023 – Recently, the first implantation of the Castor Branched Aortic Stent-Graft and Delivery System (Castor Branched Stent-Graft) and Hercules Thoracic Stent Graft with Low Profile Delivery System covered stent (Hercules™-LP Stent Graft) developed by MicroPort® Endovastec, was completed at Tan Tock Seng Hospital by Professor Glenn Tan, Professor Pua Uei, Professor Lawrence Quek, and their team. This marks the first clinical use of Endovastec’s products in Singapore.

The patient, diagnosed with a thoracic aortic aneurysm during a preoperative assessment, had a twisted and narrowed distal neck, a lengthy affected area, a large aneurysm with a maximum diameter exceeding 70 millimeters, and exhibited noticeable symptoms. This necessitated a Thoracic Endovascular Aortic Repair (TEVAR). After a comprehensive evaluation of the patient's imaging data and related measurements, the medical team decided to perform the surgery using a combination of Castor Branched Stent-Graft and Hercules-LP Stent Graft, thereby establishing a more reliable, healthy anchoring zone when isolating the aneurysm.

The operation proceeded smoothly and postoperative angiography revealed precise positioning of the CastorBranched Stent-Graft, effectively isolating the aneurysm. The near-end triple small wave segment of the stent displayed excellent sealing without any endoleak or stent migration, and the blood flow in the supra-arch branch vessels remained unobstructed, resulting in a successful surgery.

Thus far, Castor Branched Stent-Graft has been introduced into clinical application in 16 countries worldwide, successfully treating over 18,000 patients, and Hercules®-LP Stent Graft has been introduced into clinical application in 18 countries globally, effectively treating more than 58,000 patients with aortic diseases. MicroPort® Endovastec will continue its unwavering commitment to advancing comprehensive medical solutions for aortic and peripheral vascular diseases, bringing more high-quality, innovative products to global markets.

About Castor Branched Stent-Graft and Hercules-LP Stent Graft

Castor Branched Stent-Graft is designed for endovascular treatment of thoracic aortic dissection involving arch lesions and is the first approved branched aortic stent-graft for the market worldwide. Meanwhile, Hercules-LP Stent Graft adopts a Low-Profile design, which can adapt to narrower and more tortuous access arteries. It is mainly suitable for endovascular treatment of thoracic aortic aneurysm or Stanford Type B thoracic aortic dissection.

About Endovastec

Founded in 2012, Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™; SSE: 688016), an associated company of MicroPort Scientific Corporation (MicroPort®; HKEX: 00853), is a global medical device company focusing on R&D, manufacturing, and commercialization of aortic and peripheral vascular interventional devices. Its product portfolio includes thoracic and abdominal aortic stent grafts, stent grafts in surgical operation, peripheral vascular stents, drug-coated PTA balloon catheters etc. At Endovastec™, we are breaking barriers and accelerating access to provide trustworthy and universal access to state-of-the-art total solutions to vascular circulatory diseases, and to build a globally leading group of people centric enterprises of emerging medical technologies through technological innovation.

More information is available at www.endovastec.com.